X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ALG-055009 appears to be a best-in-class thyroid hormone receptor beta (THR-ß) agonist, which is being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis.
Lead Product(s): ALG-055009
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALG-055009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
ALG-055009 appears to be a best-in-class thyroid hormone receptor beta (THR-ß) agonist, which is being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Lead Product(s): ALG-055009
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALG-055009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
Aligos expects to use the net proceeds to fund the advancement of its Phase 2a NASH, ALG-055009 study evaluating its thyroid hormone receptor beta agonist, its CAM-E candidate, ALG-000184, as well as to fund discovery and research to broaden its pipeline of drug candidates.
Lead Product(s): ALG-055009
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALG-055009
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Armistice Capital
Deal Size: $92.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 23, 2023
Details:
The funding will be used to conduct nonclinical and clinical studies to advance its pan-coronavirus protease inhibitor ALG-097558, a potent, pan-coronavirus small molecule inhibitor of the viral 3CL protease, into future Phase 2/3 studies.
Lead Product(s): ALG-097558
Therapeutic Area: Infections and Infectious Diseases Product Name: ALG-097558
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: $8.5 million Upfront Cash: Undisclosed
Deal Type: Funding October 03, 2023
Details:
ALG-055009 is a potent and selective THR beta agonist which is currently being investigated for the treatment of nonalcoholic fatty liver disease (NASH).
Lead Product(s): ALG-055009
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALG-055009
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
ALG-055009 is a potent and selective THR beta agonist which is currently being investigated for the treatment of nonalcoholic fatty liver disease (NASH).
Lead Product(s): ALG-055009
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALG-055009
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2023
Details:
Under the terms of the agreement, Aligos and Amoytop will use Aligos’ oligonucleotide platform to discover, research and develop oligonucleotides for the treatment of liver diseases in the Greater China territory.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Xiamen Amoytop Biotech Co., Ltd
Deal Size: $109.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 12, 2023
Details:
ALG-055009 is a potent and selective THR beta agonist which is currently being investigated for the treatment of nonalcoholic fatty liver disease (NASH).
Lead Product(s): ALG-055009
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALG-055009
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
Phase 1 clinical data demonstrate that ALG-055009 is favorably differentiated compared to frontrunner THR-ß drug candidates such as resmetirom for nonalcoholic steatohepatitis (NASH).
Lead Product(s): ALG-055009
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALG-055009
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
ALG-125755, a small interfering RNA (siRNA) targeting the production of hepatitis B surface antigen (HBsAg), was initiated in subjects with chronic hepatitis B (CHB) in Study ALG-125755-501.
Lead Product(s): ALG-125755
Therapeutic Area: Infections and Infectious Diseases Product Name: ALG-125755
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
